OCULAR THERAPEUTIX INC's ticker is OCUL and the CUSIP is 67576A100. A total of 151 filers reported holding OCULAR THERAPEUTIX INC in Q4 2020. The put-call ratio across all filers is 0.52 and the average weighting 0.9%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $362,312 | -66.2% | 115,386 | -44.4% | 0.00% | – |
| Q2 2023 | $1,070,658 | +12.5% | 207,492 | +14.8% | 0.00% | – |
| Q1 2023 | $952,105 | +85.9% | 180,665 | -0.9% | 0.00% | – |
| Q4 2022 | $512,080 | -62.9% | 182,235 | -45.2% | 0.00% | – |
| Q3 2022 | $1,381,000 | -26.6% | 332,747 | -28.9% | 0.00% | – |
| Q2 2022 | $1,882,000 | -1.1% | 468,248 | +21.8% | 0.00% | – |
| Q1 2022 | $1,903,000 | +25.9% | 384,390 | +77.3% | 0.00% | – |
| Q4 2021 | $1,511,000 | -52.6% | 216,829 | -32.0% | 0.00% | -100.0% |
| Q3 2021 | $3,187,000 | -53.8% | 318,766 | -34.5% | 0.00% | -50.0% |
| Q2 2021 | $6,902,000 | -34.0% | 486,696 | -23.7% | 0.00% | -33.3% |
| Q1 2021 | $10,465,000 | +0.0% | 637,749 | +26.2% | 0.00% | 0.0% |
| Q4 2020 | $10,464,000 | +1000.3% | 505,527 | +304.6% | 0.00% | – |
| Q3 2020 | $951,000 | -45.8% | 124,951 | -40.7% | 0.00% | -100.0% |
| Q2 2020 | $1,754,000 | +316.6% | 210,618 | +147.4% | 0.00% | – |
| Q1 2020 | $421,000 | +262.9% | 85,136 | +189.2% | 0.00% | – |
| Q4 2019 | $116,000 | -39.9% | 29,441 | -53.5% | 0.00% | – |
| Q3 2019 | $193,000 | +28.7% | 63,286 | +86.0% | 0.00% | – |
| Q2 2019 | $150,000 | -32.7% | 34,021 | -39.3% | 0.00% | – |
| Q1 2019 | $223,000 | -33.8% | 56,063 | -33.8% | 0.00% | – |
| Q4 2018 | $337,000 | +1.2% | 84,715 | +75.0% | 0.00% | – |
| Q3 2018 | $333,000 | -11.9% | 48,407 | -13.5% | 0.00% | – |
| Q2 2018 | $378,000 | +34.5% | 55,940 | +29.7% | 0.00% | – |
| Q1 2018 | $281,000 | +80.1% | 43,124 | +23.3% | 0.00% | – |
| Q4 2017 | $156,000 | -31.3% | 34,967 | -4.9% | 0.00% | – |
| Q3 2017 | $227,000 | -26.8% | 36,759 | +10.0% | 0.00% | – |
| Q2 2017 | $310,000 | +4.4% | 33,417 | +4.4% | 0.00% | – |
| Q1 2017 | $297,000 | -28.9% | 31,995 | -35.9% | 0.00% | – |
| Q4 2016 | $418,000 | -15.7% | 49,898 | -30.9% | 0.00% | – |
| Q3 2016 | $496,000 | +109.3% | 72,183 | +51.0% | 0.00% | – |
| Q2 2016 | $237,000 | -13.2% | 47,814 | +268.0% | 0.00% | – |
| Q2 2015 | $273,000 | – | 12,993 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SUMMER ROAD LLC | 3,804,788 | $15,105,000 | 43.34% |
| Versant Venture Management, LLC | 2,215,384 | $8,795,074,000 | 2.90% |
| Opaleye Management Inc. | 1,900,000 | $7,543,000 | 2.09% |
| SV Health Investors, LLC | 628,236 | $2,494,000 | 1.46% |
| Endurant Capital Management LP | 716,124 | $2,843,000 | 1.12% |
| DELTEC ASSET MANAGEMENT LLC | 824,747 | $3,274,000 | 0.72% |
| NOTTINGHAM ADVISORS, INC. | 146,946 | $583,000 | 0.08% |
| Jump Trading, LLC | 39,255 | $156,000 | 0.05% |
| Man Group plc | 1,723,456 | $6,842,000 | 0.03% |
| JGP Global Gestao de Recursos Ltda. | 13,880 | $55,000 | 0.02% |